GLUE Monte Rosa Therapeutics, Inc. Insider Trading

Director Leo Chandra P. bought 10,000 (10.0K shares) of GLUE at $5.84; stock down 45.3% from 52-week high, company unprofitable with $-23.9M net income.

Leo Chandra P. established an initial 10,000-share position in Monte Rosa Therapeutics at $5.84 per share, representing his first purchase in the company. The transaction occurs in a deteriorated price environment: the stock trades 45.3% below its 52-week high of $10.36 and has declined 19.6% over the prior 90 days. Monte Rosa is unprofitable with reported net income of $-23.9M against quarterly revenue of $9.2M, indicating significant cash burn in its therapeutic development stage. As a director, Chandra's initial stake warrants attention to whether it signals foundational confidence in the platform or is a routine board-related acquisition, though the combination of losses and valuation decline from recent peaks creates a different context than a purchase near all-time highs.

Versant VC VI sells 157,895 shares ($1.5M) across 3 transactions at $9.22–$9.66; reduces GLUE stake to 1.57M shares

Versant Venture Capital VI, L.P., a 10% owner of Monte Rosa Therapeutics, executed 3 separate sales totaling 157,895 shares for $1,491,041.15 on 2024-10-28 and 2024-10-29, reducing its holdings by 9.1%. The sales occurred at a blended average price of $9.44, near the 52-week high of $9.48. Notably, the stock has surged 74.0% over the prior 30 days and 111.0% over the prior 90 days, placing these sales in a period of significant upward momentum. The company is unprofitable (latest quarter net income of $-30,310,000.00) with modest revenue of $4,695,000.00, and Versant's prior 4 sales at this ticker have consistently faced negative 30-day returns (-15.5%, -20.0%, -17.9%, -17.8%), suggesting a pattern of selling into strength without subsequent gains sustaining. The timing of this substantial position reduction during a steep rally, combined with the company's fundamental challenges and the insider's historical underperformance on GLUE sales, merits investor scrutiny.

Versant Venture Capital VI sold 1,132,566 shares (18.2% of holdings) at $6.53 on 2024-09-20, reducing stake to 5,099,336 shares

Versant Venture Capital VI, a 10% owner of Monte Rosa Therapeutics (GLUE), sold 1,132,566 shares at $6.53, reducing its position by 18.2% in a single transaction valued at $7,395,202.95. This sale follows three additional GLUE sales in the prior week (September 11, 12, and 13), suggesting a deliberate staged exit from the position rather than an isolated transaction. The company's fundamentals remain challenged: Monte Rosa generated only $4,695,000 in latest-quarter revenue while reporting a net loss of $-30,310,000, with a market cap of $349,211,368.56. The current stock price of $5.69 is 32.7% below the 52-week high of $8.46 and has declined 10.1% over the past 30 days, though it is up 54.2% over 90 days from its recent lows.

Versant Venture Capital VI sold 567,213 shares (8.3% reduction) at $6.00 avg, retaining 6.23M shares; stock +35.1% in 30 days

Versant Venture Capital VI, a 10% owner, executed 3 separate sales totaling 567,213 shares for $3,404,791.10 ($3.4M) at an average price of $6.00, reducing its position from 6,799,115 to 6,231,902 shares. The sales came during a period of strong short-term momentum—the stock has risen 35.1% over the past 30 days and 58.8% over 90 days—yet remains 28.1% below its 52-week high. The company remains unprofitable, with quarterly revenue of $4,695,000.00 and a net loss of $30,310,000.00. This is the insider's first sale across its entire open-market history. The partial reduction in a 10% strategic stake at a time of elevated valuation and sustained losses warrants attention from investors tracking institutional conviction levels and capital allocation patterns at early-stage biotech firms.